Innocan Pharma's Narrative Review on Synthetic Cannabidiol to be Presented at PAINWEEK 2025
Innocan Pharma Corporation, a trailblazer in the pharmaceutical and biotechnology sectors, is set to present its latest narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" at the prestigious PAINWEEK 2025 conference. This event will take place in September in Las Vegas, Nevada, and is renowned for convening a diverse group of clinicians, researchers, and educators focused on pain management.
The narrative review has undergone a rigorous peer-review process, ensuring its acceptance as a vital contribution to the ongoing discussions about pain management strategies. This review elucidates the potential of synthetic cannabidiol (CBD) in the form of long-acting extended-release formulations. By providing a well-tolerated, non-opioid analgesic option, this research addresses an urgent concern regarding the opioid crisis, demonstrating Innocan's stark commitment to exploring alternatives that reduce opioid dependency.
At the forefront of this initiative is Innocan's LPT-CBD, a pioneering injectable liposomal formulation designed for effective, sustained release of synthetic CBD. Its efficacy has been substantiated through exhaustive research, indicating that it can achieve stable plasma CBD levels for periods up to four weeks, offering prolonged pain alleviation and exceptional tolerability. With such promising results, LPT-CBD represents a significant advancement in the realm of chronic pain management, and it will command attention during the PAINWEEK conference, where thousands of healthcare professionals and potential pharmaceutical partners are expected to gather.
Chief Executive Officer Iris Bincovich expressed pride in being selected for presentation at such a notable conference, stating, "We are honored to be included among the esteemed voices presenting at PAINWEEK this year. This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field."
Innocan's dedication extends beyond the boundaries of pharmaceuticals. The company is also actively engaged in promoting wellness through a range of high-performance self-care and beauty products, cultivating a holistic approach to health. Through its subsidiary, BI Sky Global Ltd., Innocan is further focusing on advanced and targeted online sales strategies to strengthen its offering in the consumer market.
As Innocan prepares for its appearance at PAINWEEK, it is also mindful of the broader implications of its research in light of the ongoing opioid crisis. The company is resolute in its goal to become a key player in transforming the landscape of pain management. With innovative approaches like LPT-CBD, Innocan Pharma is positioning itself at the leading edge of a revolution in chronic pain treatment, ensuring that there are viable, non-opioid alternatives available to those who need them most.
For more information on Innocan Pharma and its initiatives, visit www.innocanpharma.com.
The narrative review has undergone a rigorous peer-review process, ensuring its acceptance as a vital contribution to the ongoing discussions about pain management strategies. This review elucidates the potential of synthetic cannabidiol (CBD) in the form of long-acting extended-release formulations. By providing a well-tolerated, non-opioid analgesic option, this research addresses an urgent concern regarding the opioid crisis, demonstrating Innocan's stark commitment to exploring alternatives that reduce opioid dependency.
At the forefront of this initiative is Innocan's LPT-CBD, a pioneering injectable liposomal formulation designed for effective, sustained release of synthetic CBD. Its efficacy has been substantiated through exhaustive research, indicating that it can achieve stable plasma CBD levels for periods up to four weeks, offering prolonged pain alleviation and exceptional tolerability. With such promising results, LPT-CBD represents a significant advancement in the realm of chronic pain management, and it will command attention during the PAINWEEK conference, where thousands of healthcare professionals and potential pharmaceutical partners are expected to gather.
Chief Executive Officer Iris Bincovich expressed pride in being selected for presentation at such a notable conference, stating, "We are honored to be included among the esteemed voices presenting at PAINWEEK this year. This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field."
Innocan's dedication extends beyond the boundaries of pharmaceuticals. The company is also actively engaged in promoting wellness through a range of high-performance self-care and beauty products, cultivating a holistic approach to health. Through its subsidiary, BI Sky Global Ltd., Innocan is further focusing on advanced and targeted online sales strategies to strengthen its offering in the consumer market.
As Innocan prepares for its appearance at PAINWEEK, it is also mindful of the broader implications of its research in light of the ongoing opioid crisis. The company is resolute in its goal to become a key player in transforming the landscape of pain management. With innovative approaches like LPT-CBD, Innocan Pharma is positioning itself at the leading edge of a revolution in chronic pain treatment, ensuring that there are viable, non-opioid alternatives available to those who need them most.
For more information on Innocan Pharma and its initiatives, visit www.innocanpharma.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.